TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT04638153

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.
“The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.”

The sponsor’s own words in the registry.

Life of this trial

202020212022202320242025Registered2020-09-15Started2020-12-02Primary completion2023-01-16Stopped2023-03-27Results posted2024-02-15

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Pfizer
Sponsor type
Industry
Conditions
Achondroplasia
Interventions
Recifercept
Participants
60
Sites
16
Countries
Australia, Belgium, Denmark, Italy, Japan, Portugal, Spain, United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.